Analysts on Wall Street project that Steris (STE) will announce quarterly earnings of $2.58 per share in its forthcoming report, representing an increase of 7.1% year over year. Revenues are projected to reach $1.48 billion, increasing 4.2% from the same quarter last year. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock. While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding. With that in mind, let's delve into the average projections of some Steris metrics that are commonly tracked and projected by analysts on Wall Street. It is projected by analysts that the 'Revenues- Healthcare' will reach $1.05 billion. The estimate indicates a change of +4.5% from the prior-year quarter. Analysts forecast 'Revenues- Healthcare Products- Service' to reach $360.96 million. The estimate suggests a change of +5.1% year over year. Based on the collective assessment of analysts, 'Revenues- Healthcare Products- Capital equipment' should arrive at $327.37 million. The estimate indicates a change of -1.3% from the prior-year quarter. The average prediction of analysts places 'Revenues- Healthcare Products- Consumables' at $364.74 million. The estimate indicates a year-over-year change of +9.6%. The combined assessment of analysts suggests that 'Revenues- Applied Sterilization Technologies (AST)' will likely reach $269.92 million. The estimate points to a change of +7.6% from the year-ago quarter. Analysts predict that the 'Revenues- Life Sciences' will reach $155.49 million. The estimate suggests a change of -3.2% year over year. Analysts' assessment points toward 'Revenues- Life Sciences- Service' reaching $41.39 million. The estimate suggests a change of -10% year over year. According to the collective judgment of analysts, 'Revenues- Life Sciences- Consumables' should come in at $80.04 million. The estimate indicates a change of +13.7% from the prior-year quarter. Story Continues Analysts expect 'Revenues- Life Sciences- Capital equipment' to come in at $35.43 million. The estimate indicates a year-over-year change of -19.9%. The consensus estimate for 'Operating income / (loss)- Healthcare' stands at $255.95 million. Compared to the current estimate, the company reported $245.22 million in the same quarter of the previous year. The collective assessment of analysts points to an estimated 'Operating income / (loss)- Applied Sterilization Technologies (AST)' of $118.69 million. Compared to the present estimate, the company reported $114.22 million in the same quarter last year. The consensus among analysts is that 'Operating income / (loss)- Life Sciences' will reach $64.54 million. The estimate is in contrast to the year-ago figure of $64.49 million. View all Key Company Metrics for Steris here>>> Steris shares have witnessed a change of +4% in the past month, in contrast to the Zacks S&P 500 composite's +13.7% move. With a Zacks Rank #2 (Buy), STE is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
What Analyst Projections for Key Metrics Reveal About Steris (STE) Q4 Earnings
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...